COMPOSITIONS AND METHODS TO TREAT CANCER
Provided herein are methods and combination therapies useful for the treatment of cancer. In particular, provided herein are methods and combination therapies for treating cancer by administering a combination therapy comprising (a) the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and (b) at least one DNA damaging agent, or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions and pharmaceutical combinations comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one DNA damaging agent, or a pharmaceutically acceptable salt thereof.
1 - 39 . (canceled)
40 . A method of treating cancer in a subject in need thereof comprising administering to the subject
(a) a therapeutically effective amount of compound of Formula (I),
or a pharmaceutically acceptable salt thereof, and
(b) a therapeutically effective amount of at least one DNA damaging agent, or a pharmaceutically acceptable salt thereof.
41 . The method of claim 40 , wherein (a) and (b) are administered concurrently.
42 . The method of claim 40 , wherein (a) and (b) are administered sequentially in either order.
43 . The method of claim 40 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered at a dose from about 1 mg to about 15 mg.
44 . The method of claim 40 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject three times a day, twice a day, daily, every other day, three times a week, twice a week, weekly, every other week, twice a month, or monthly.
45 . The method of claim 44 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered to the subject daily.
46 . The method of claim 40 , wherein the at least one DNA damaging agent, or a pharmaceutically acceptable salt thereof, is a single DNA damaging agent selected from cyclophosphamide, mechlorethamine, chlorambucil, melphalan, dacarbazine, temozolomide, cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, satraplatin, carmustine, lomustine, semustine, bendamustine, nimustine, ranimustine, uramustine, busulfan, chlormethine, fotemustine, ifosfamide, streptozocin, bleomycin, mitomycin, altretamine, irinotecan, topotecan, camptothecin, lamellarin, etoposide, teniposide, doxorubicin, daunorubicin, epirubicin, idarubicin, valrubicin, tafluposide mitoxantrone, and amsacrine; and pharmaceutically acceptable salts thereof.
47 . The method of claim 40 , wherein the at least one DNA damaging agent, or a pharmaceutically acceptable salt thereof, is two DNA damaging agents selected from cyclophosphamide, mechlorethamine, chlorambucil, melphalan, dacarbazine, temozolomide, cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, satraplatin, carmustine, lomustine, semustine, bendamustine, nimustine, ranimustine, uramustine, busulfan, chlormethine, fotemustine, ifosfamide, streptozocin, bleomycin, mitomycin, altretamine, irinotecan, topotecan, camptothecin, lamellarin, etoposide, teniposide, doxorubicin, daunorubicin, epirubicin, idarubicin, valrubicin, tafluposide mitoxantrone, and amsacrine; and pharmaceutically acceptable salts thereof.
48 . The method of claim 46 , wherein the at least one DNA damaging agent, or a pharmaceutically acceptable salt thereof, is a single DNA damaging agent selected from cisplatin, carboplatin, and oxaliplatin.
49 . The method of claim 48 , wherein the at least one DNA damaging agent is cisplatin.
50 . The method of claim 48 , wherein the at least one DNA damaging agent is carboplatin.
51 . The method of claim 48 , wherein the at least one DNA damaging agent is oxaliplatin.
52 . The method of claim 40 , wherein the compound of Formula (I) is present as a pharmaceutically acceptable salt.
53 . The method of claim 40 , wherein the compound of Formula (I) is present as the besylate salt.
54 . The method of claim 40 , wherein the compound of Formula (I) is present as the free base.
55 . The method of claim 40 , wherein the cancer is selected from: colorectal cancer, breast cancer, esophageal cancer, gastric cancer, pancreatic cancer, liver cancer, adrenocortical cancer, prostate cancer, liposarcoma, thyroid cancer, bladder cancer, kidney cancer, melanoma, squamous cell carcinoma, cervical cancer, testicular cancer, neuroblastoma, small cell lung cancer, non-small cell lung cancer, glioblastoma multiforme, astrocytoma, ovarian cancer, glioma, medulloblastoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histocytic lymphoma, Burkitt's lymphoma, AIDS-related Kaposi's sarcoma, multiple myeloma, chronic lymphocytic leukemia, chronic granulocytic leukemia, acute myelogenous leukemia, and acute lymphoblastic leukemia.
56 . A pharmaceutical composition comprising
(a) the compound of Formula (I),
or a pharmaceutically acceptable salt thereof,
(b) at least one DNA damaging agent, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutical excipients.
57 . The pharmaceutical composition of claim 56 , wherein the at least one DNA damaging agent, or a pharmaceutically acceptable salt thereof, is a single DNA damaging agent selected from cyclophosphamide, mechlorethamine, chlorambucil, melphalan, dacarbazine, temozolomide, cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, satraplatin, carmustine, lomustine, semustine, bendamustine, nimustine, ranimustine, uramustine, busulfan, chlormethine, fotemustine, ifosfamide, streptozocin, bleomycin, mitomycin, altretamine, irinotecan, topotecan, camptothecin, lamellarin, etoposide, teniposide, doxorubicin, daunorubicin, epirubicin, idarubicin, valrubicin, tafluposide mitoxantrone, and amsacrine; and pharmaceutically acceptable salts thereof.
58 . A method of inhibiting cancer cell proliferation in a subject in need thereof, the method comprising contacting the cancer cell with
(a) a compound of Formula (I),
or a pharmaceutically acceptable salt thereof, and
(b) at least one DNA damaging agent, or a pharmaceutically acceptable salt thereof.
59 . The method of claim 58 , wherein the at least one DNA damaging agent, or a pharmaceutically acceptable salt thereof, is a single DNA damaging agent selected from cyclophosphamide, mechlorethamine, chlorambucil, melphalan, dacarbazine, temozolomide, cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, satraplatin, carmustine, lomustine, semustine, bendamustine, nimustine, ranimustine, uramustine, busulfan, chlormethine, fotemustine, ifosfamide, streptozocin, bleomycin, mitomycin, altretamine, irinotecan, topotecan, camptothecin, lamellarin, etoposide, teniposide, doxorubicin, daunorubicin, epirubicin, idarubicin, valrubicin, tafluposide mitoxantrone, and amsacrine; and pharmaceutically acceptable salts thereof.